Bristol Myers partners with Bain Capital to launch a new autoimmune-focused biotech, out-licensing five key immunology assets ...

(Reuters) -Drugmaker Bristol Myers Squibb and private equity firm Bain Capital will launch an independent company focused on ...

Bristol Myers will get a nearly 20% stake in the startup, which will be led by one of its former executives, Dan Lynch, and ...

Bristol Myers Squibb is spinning off a fresh company armed with five autoimmune disease drugs and $300 million in Bain ...

The newly formed biotech launches with five promising autoimmune candidates, $300 million in funding, and leadership from ...

Bristol Myers Squibb and Bain Capital launch a new biopharma firm focused on autoimmune disease treatments, starting with 5 ...

US pharma major Bristol Myers Squibb and Bain Capital announced the creation of a new independent biopharmaceutical company ...

Bristol Myers Squibb and Bain Capital have formed a new independent biopharmaceutical company focused on developing new ...

BMS is spinning out a new company with five immunology assets, including oral drugs being developed for systemic lupus ...

A new startup offering an AI-enabled threat-hunting platform is emerging from stealth today with backing from Bain Capital ...

HS Hyosung Advanced Materials has selected Bain Capital as the preferred bidder for its tire steel cord business unit. According to the investment banking (IB) industry on the 28th, HS Hyosung ...

The company will begin with five potential treatments for autoimmune diseases in-licensed from Bristol Myers Squibb, which ...